Billions of National Institutes of Health Grants Could Be Jeopardized: Here’s Why! 

Why National Institutes of Health Grants Could Be Jeopardized?

The claim centers around the alleged failure of the Biden administration to correctly reappoint more than a dozen leaders at the National Institutes of Health (NIH). CBS News reported that a letter from the House Energy & Commerce Committee, led by Republican chair Rep. Cathy McMorris Rodgers, states that the failure to reappoint these officials raises questions about the legality of over $25 billion in federal biomedical research grants awarded in 2022 alone.

The committee’s concerns stem from the interpretation of the 21st Century Cures Act, which imposes term limits on directors at the National Institutes of Health grants. When the term limits of 14 officials came due at the end of 2021, the Biden administration argues that the NIH director correctly reappointed them. However, the committee argues that the reappointments fell short of the requirements outlined in the law. The dispute centers on whether the reappointments should have been made by the Secretary of Health and Human Services, Xavier Becerra, or the NIH director.

The Biden administration has rebutted the committee’s accusations, stating that they did not violate the law. An HHS official familiar with the matter said the committee was misrepresenting the requirements. However, the committee contends that the reappointments were not conducted by the law and has raised concerns about the legality of the grants.

READ ALSO: Proposed Medicare Cuts Threaten Patient Access To Vital Care, Warns Healthcare Experts

Future Of National Institutes of Health Grants

The dispute over the reappointments raises uncertainties about the future of National Institutes of Health grants and potentially opens the door to legal challenges. The committee’s investigation into the issue is ongoing, and it has requested further information from the HHS and NIH officials. The Biden administration has yet to fill key vacancies in the NIH leadership, with the agency lacking a director since December 2021. The nomination of Dr. Monica Bertagnolli to fill the role is awaiting Senate confirmation, but progress on the nomination has been stalled due to concerns about drug pricing raised by Independent Sen. Bernie Sanders.

The outcome of this dispute could have significant implications for the future of National Institutes of Health grants and the biomedical research supported by these funds. It remains to be seen how this issue will be resolved and whether it will impact the continuity and effectiveness of federal biomedical research programs.

READ ALSO: $19 Billion California Health Care Deal; Healthcare Field Lawmakers And Industry Rivals Reached A Deal On How To Spend The Fund